CJC-1295 No DAC + Ipamorelin (10mg Blend): Growth Hormone Secretagogue Research Overview

CJC-1295 No DAC + Ipamorelin is a research peptide combination frequently studied for its effects on the growth hormone (GH) axis. The blend combines two compounds that act through different receptor pathways involved in growth hormone regulation. CJC-1295 No DAC (also known as Modified GRF 1-29) functions as a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin acts as a selective growth hormone secretagogue receptor (GHS-R1a) agonist. Researchers are interested in this pairing because it targets complementary mechanisms involved in GH release. (Peptide.co)

What Is CJC-1295 No DAC?

CJC-1295 No DAC is a modified version of GHRH designed to resist rapid enzymatic breakdown while maintaining a relatively short duration of action. Unlike the DAC (Drug Affinity Complex) version, which remains active for days, the No DAC version produces a shorter, more physiologic pulse of growth hormone signaling. (Peptide.co)

Researchers study CJC-1295 No DAC for:

• Growth hormone release dynamics
• IGF-1 signaling pathways
• Endocrine feedback mechanisms
• Growth hormone pulsatility research

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin receptor (GHS-R1a). Unlike older growth hormone secretagogues, Ipamorelin has been studied for its relative selectivity toward GH release pathways. Researchers use it to investigate the role of ghrelin signaling in endocrine regulation and metabolism. (Peptide Science Institute)

Areas of scientific interest include:

• Growth hormone secretion
• Ghrelin receptor biology
• Endocrine signaling
• Metabolic regulation research

How the Combination Works

The scientific rationale for combining these peptides is based on their activity at different receptors.

CJC-1295 No DAC Pathway

CJC-1295 activates the GHRH receptor in pituitary somatotroph cells, promoting growth hormone synthesis and release through cAMP-mediated signaling pathways. (Peptide.co)

Ipamorelin Pathway

Ipamorelin activates the ghrelin receptor pathway, stimulating intracellular calcium signaling associated with GH secretion. (Peptide.co)

Dual-Receptor Research Model

Researchers study the combination because simultaneous activation of both pathways may produce a larger GH response than either pathway alone. This concept is commonly described as receptor complementarity or pathway synergy in GH-axis research. (Peptide.co)

Research Applications

The CJC-1295 No DAC + Ipamorelin combination is investigated in studies involving:

• Growth hormone physiology
• IGF-1 signaling
• Endocrine regulation
• Body composition research
• Recovery and tissue remodeling pathways
• Sleep and circadian hormone research

Most published evidence relates to the individual compounds, while direct studies of the combination remain limited. (Peptide Science Institute)

CJC-1295 With DAC vs No DAC

An important distinction in research is the difference between the two forms of CJC-1295:

Feature	No DAC	With DAC
Activity Pattern	Short GH pulse	Sustained GH elevation
Half-Life	Approximately 30 minutes	Several days
Research Focus	Physiologic pulsatility	Continuous exposure
Combination with Ipamorelin	Commonly studied	Less common

These differences can significantly affect experimental design and interpretation. (Peptide.co)

Scientific Limitations

Researchers should consider several limitations:

• Few published studies evaluate the exact combination directly.
• Most evidence comes from individual peptide research.
• Long-term effects remain incompletely understood.
• Human clinical data are limited compared with approved therapies. (Peptide Science Institute)

Regulatory Status

Important considerations include:

• CJC-1295 No DAC and Ipamorelin are generally classified as investigational research compounds.
• They are not approved as general therapeutic medications by major regulatory agencies.
• Research use differs from approved medical use.
• Safety and efficacy for many proposed applications remain under investigation. (Peptide Science Institute)

Conclusion

CJC-1295 No DAC + Ipamorelin (10mg Blend) is a research-focused combination studied for its effects on growth hormone regulation through dual receptor activation. By targeting both the GHRH receptor and the ghrelin receptor, researchers use this pairing to investigate GH pulsatility, endocrine signaling, and metabolic physiology. While the mechanistic rationale is well established, direct clinical evidence for the combination remains limited, and further research is needed to clarify its long-term biological effects. (Peptide.co)